Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 12

Trial Status

Recruiting1
Other2

Role Distribution

Principal Investigator3
PI Rate100%

Activity Timeline

Clinical Trials (3)

NCT07619599Phase 1Recruiting
A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving Pembrolizumab
Metastatic Lung Non-Small Cell CarcinomaMetastatic Malignant Neoplasm in the BrainOligoprogressive Lung Non-Small Cell Carcinoma+1 more
PrincipalinvestigatorStart date: 2026-09-01
NCT01923506Phase 1Active Not Recruiting
Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer After Undergoing Surgery
Recurrent Prostate CancerStage I Prostate CancerStage IIA Prostate Cancer+2 more
PrincipalinvestigatorStart date: 2013-11-25

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Stephen Michael Hahn

Abramson Cancer Center at Penn Medicine

Related
6 trials

Shared therapeutic areas:

Recurrent Prostate CancerStage I Prostate CancerStage IIA Prostate Cancer+1 more

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score12%

Michael Schweizer

Fred Hutch/University of Washington Cancer Consortium

Related
11 trials

Shared therapeutic areas:

Metastatic Lung Non-Small Cell CarcinomaMetastatic Malignant Solid NeoplasmStage IV Lung Cancer AJCC v8

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score9%

Robert Montgomery

Fred Hutch/University of Washington Cancer Consortium

Related
6 trials

Shared therapeutic areas:

Stage IIA Prostate CancerStage IIB Prostate CancerStage III Prostate Cancer

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score9%

Arya Amini

City of Hope Medical Center

Related
7 trials

Shared therapeutic areas:

Stage IV Lung Cancer AJCC v8Metastatic Lung Non-Small Cell CarcinomaMetastatic Malignant Neoplasm in the Brain

Worked with same sponsors:

City of Hope Medical CenterNational Cancer Institute (NCI)
Similarity Score9%

Kathrin Milbury

M.D. Anderson Cancer Center

Related
7 trials

Shared therapeutic areas:

Stage IV Lung Cancer AJCC v8Metastatic Malignant Neoplasm in the BrainMetastatic Malignant Solid Neoplasm

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score9%

Aung Naing, Md

M.D. Anderson Cancer Center

Related
16 trials

Shared therapeutic areas:

Metastatic Lung Non-Small Cell CarcinomaMetastatic Malignant Solid NeoplasmStage IV Lung Cancer AJCC v8

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score9%

Stanislaw R. Burzynski, MD, PhD

Burzynski Research Institute

Related
62 trials

Shared therapeutic areas:

Recurrent Prostate CancerStage III Prostate Cancer
Similarity Score6%

Glenn Lesser, MD

Wake Forest University Health Sciences

Related
10 trials

Shared therapeutic areas:

Stage I Prostate CancerStage III Prostate Cancer

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score6%

Aminah Jatoi, MD

Mayo Clinic

Related
29 trials

Shared therapeutic areas:

Metastatic Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score6%

Jun Mao, MD, MSCE

Memorial Sloan Kettering Cancer Center

Related
13 trials

Shared therapeutic areas:

Stage I Prostate CancerStage III Prostate Cancer
Similarity Score6%

Publications (0)

No publications found for this investigator.

Clinical Trials (3)

Showing 3 of 3 trials

NCT07619599Phase 1PrincipalInvestigator

A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving Pembrolizumab

Metastatic Lung Non-Small Cell CarcinomaMetastatic Malignant Neoplasm in the BrainOligoprogressive Lung Non-Small Cell Carcinoma+1 more
Recruiting
NCT01923506Phase 1PrincipalInvestigator

Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer After Undergoing Surgery

Recurrent Prostate CancerStage I Prostate CancerStage IIA Prostate Cancer+2 more
Active Not Recruiting
NCT05728372Early Phase 1PrincipalInvestigator

64Cu-DOTA Pembrolizumab for Imaging Metastatic Solid Tumors in Patients Receiving Stereotactic Body Radiation

Metastatic Malignant Solid Neoplasm
Withdrawn

All 3 trials loaded